Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis - PubMed (original) (raw)
. 1986 Jun 15;136(12):4456-9.
- PMID: 3711661
Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis
M E Sanders et al. J Immunol. 1986.
Abstract
A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barré Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 micrograms/ml; range, 0 to 7.1 micrograms/ml) and 16 of 21 patients with MS (mean, 1.83 micrograms/ml; range, 0 to 7.5 micrograms/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 micrograms/ml; range, 0 to 1.7 micrograms/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.
Similar articles
- Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA. Koski CL, et al. J Clin Invest. 1987 Nov;80(5):1492-7. doi: 10.1172/JCI113231. J Clin Invest. 1987. PMID: 3680509 Free PMC article. - Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases.
Sanders ME, Alexander EL, Koski CL, Shin ML, Sano Y, Frank MM, Joiner KA. Sanders ME, et al. Ann N Y Acad Sci. 1988;540:387-8. doi: 10.1111/j.1749-6632.1988.tb27109.x. Ann N Y Acad Sci. 1988. PMID: 3207265 No abstract available. - Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
Rus H, Cudrici C, Niculescu F, Shin ML. Rus H, et al. J Neuroimmunol. 2006 Nov;180(1-2):9-16. doi: 10.1016/j.jneuroim.2006.07.009. Epub 2006 Aug 14. J Neuroimmunol. 2006. PMID: 16905199 Review. - Immune-mediated demyelination.
Hartung HP. Hartung HP. Ann Neurol. 1993 Jun;33(6):563-7. doi: 10.1002/ana.410330602. Ann Neurol. 1993. PMID: 8498835 Review.
Cited by
- Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA. Koski CL, et al. J Clin Invest. 1987 Nov;80(5):1492-7. doi: 10.1172/JCI113231. J Clin Invest. 1987. PMID: 3680509 Free PMC article. - Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis.
Linington C, Lassmann H, Morgan BP, Compston DA. Linington C, et al. Acta Neuropathol. 1989;79(1):78-85. doi: 10.1007/BF00308961. Acta Neuropathol. 1989. PMID: 2589027 - Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.
Morgan BP. Morgan BP. Biochem J. 1989 Nov 15;264(1):1-14. doi: 10.1042/bj2640001. Biochem J. 1989. PMID: 2690818 Free PMC article. Review. No abstract available. - Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines.
Natarajan R, Hagman S, Hämälainen M, Leppänen T, Dastidar P, Moilanen E, Elovaara I. Natarajan R, et al. Mult Scler Int. 2015;2015:371734. doi: 10.1155/2015/371734. Epub 2015 Nov 8. Mult Scler Int. 2015. PMID: 26634156 Free PMC article. - Reversible injury of cultured rat oligodendrocytes by complement.
Scolding NJ, Houston WA, Morgan BP, Campbell AK, Compston DA. Scolding NJ, et al. Immunology. 1989 Aug;67(4):441-6. Immunology. 1989. PMID: 2767708 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical